Novo Nordisk is trading at $42.27, +6.34%, after November 4 third-quarter results beat expectations and it raised its 2026 outlook for the third time this year.
- Wegovy pill sales reached DKK 5.39 billion, ahead of analyst expectations; adjusted operating profit rose 27% at constant exchange rates.
- Adjusted sales and operating-profit growth outlook: -2% to +2%, versus -6% to 0% previously.
- Reuters and CNBC reported a positive earnings and guidance reaction; no volume figure was available in the sources reviewed.